Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recently published medtech-related HTAs in Wales

16 Mar 2023

Health Technology Wales (HTW) is a national body working to improve the quality of care in Wales. It is funded by Welsh Government and hosted within NHS Wales but independent of both. HTW covers medical devices, diagnostics, procedures, psychological therapies, models of care, and social care support, excluding pharmaceuticals.

HTW uses a staged process of assessment by developing three types of documents. Anyone can suggest a topic, and HTW also performs active horizon scanning. The topic exploration report (TER) aimed to assess whether there is enough available evidence to proceed with a full appraisal and whether the topic meets the appraisal selection criteria. Based on the TER conclusions, HTW's Assessment Group decides whether to progress this topic further. If yes, the following two documents are developed: Evidence Appraisal Report (EAR) and Guidance (GUI). Recommendations are not mandatory; the status of HTW guidance is "adopt or justify," meaning that the local health board and other relevant bodies are expected to report on how they have considered the appraisal and guidance. If they have chosen not to adopt HTW guidance, they are asked to outline their rationale and justify their decision.

No appraisals for Medtech were completed in January-February 2023, so no Evidence Appraisal Report (EAR) and Guidance (GUI) were published.

Sixteen Medtech-related Topic Exploration Reports (TER) were published in January-February 2023, for which HTW will not proceed to develop full appraisals. Some of those topics are provided below:

  • Stereotactic ablative body radiotherapy (SABR) for locally advanced exocrine pancreatic cancer;
  • Leadless cardiac pacemakers for bradyarrhythmias due to contraindications for conventional pacemakers;
  • Active middle ear hearing implants for complex hearing conditions;
  • Gracilis free-functioning muscle transfer (FFMT) to restore upper limb function in brachial plexus injury;
  • Ex-vivo lung perfusion for advanced pulmonary disease;
  • Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure;
  • Stereotactic radiosurgery for trigeminal neuralgia.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.